nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—ABCB1—lung cancer	0.236	1	CbGaD
Fesoterodine—ABCB1—Topotecan—lung cancer	0.0356	0.0701	CbGbCtD
Fesoterodine—ABCB1—Gefitinib—lung cancer	0.0326	0.0641	CbGbCtD
Fesoterodine—CYP2D6—Gefitinib—lung cancer	0.0307	0.0604	CbGbCtD
Fesoterodine—ABCB1—Vinorelbine—lung cancer	0.0251	0.0494	CbGbCtD
Fesoterodine—CYP2D6—Vinorelbine—lung cancer	0.0236	0.0465	CbGbCtD
Fesoterodine—CYP3A4—Topotecan—lung cancer	0.0213	0.042	CbGbCtD
Fesoterodine—ABCB1—Crizotinib—lung cancer	0.02	0.0393	CbGbCtD
Fesoterodine—CYP3A4—Gefitinib—lung cancer	0.0195	0.0384	CbGbCtD
Fesoterodine—ABCB1—Gemcitabine—lung cancer	0.0195	0.0384	CbGbCtD
Fesoterodine—ABCB1—Erlotinib—lung cancer	0.0192	0.0379	CbGbCtD
Fesoterodine—CYP3A4—Teniposide—lung cancer	0.0189	0.0372	CbGbCtD
Fesoterodine—CYP2D6—Erlotinib—lung cancer	0.0181	0.0357	CbGbCtD
Fesoterodine—ABCB1—Paclitaxel—lung cancer	0.0176	0.0347	CbGbCtD
Fesoterodine—ABCB1—Irinotecan—lung cancer	0.0174	0.0342	CbGbCtD
Fesoterodine—ABCB1—Vinblastine—lung cancer	0.0155	0.0304	CbGbCtD
Fesoterodine—CYP3A4—Vinorelbine—lung cancer	0.015	0.0296	CbGbCtD
Fesoterodine—CYP2D6—Vinblastine—lung cancer	0.0146	0.0287	CbGbCtD
Fesoterodine—ABCB1—Cisplatin—lung cancer	0.0142	0.0279	CbGbCtD
Fesoterodine—ABCB1—Etoposide—lung cancer	0.0139	0.0274	CbGbCtD
Fesoterodine—ABCB1—Docetaxel—lung cancer	0.0127	0.0251	CbGbCtD
Fesoterodine—CYP3A4—Crizotinib—lung cancer	0.012	0.0235	CbGbCtD
Fesoterodine—CYP3A4—Erlotinib—lung cancer	0.0115	0.0227	CbGbCtD
Fesoterodine—CYP3A4—Paclitaxel—lung cancer	0.0106	0.0208	CbGbCtD
Fesoterodine—CYP3A4—Irinotecan—lung cancer	0.0104	0.0205	CbGbCtD
Fesoterodine—ABCB1—Doxorubicin—lung cancer	0.0095	0.0187	CbGbCtD
Fesoterodine—CYP3A4—Vinblastine—lung cancer	0.00926	0.0182	CbGbCtD
Fesoterodine—ABCB1—Methotrexate—lung cancer	0.0092	0.0181	CbGbCtD
Fesoterodine—CYP2D6—Doxorubicin—lung cancer	0.00895	0.0176	CbGbCtD
Fesoterodine—CYP3A4—Etoposide—lung cancer	0.00834	0.0164	CbGbCtD
Fesoterodine—CYP3A4—Docetaxel—lung cancer	0.00763	0.015	CbGbCtD
Fesoterodine—CYP3A4—Doxorubicin—lung cancer	0.00569	0.0112	CbGbCtD
Fesoterodine—Urethral disorder—Docetaxel—lung cancer	0.000243	0.00135	CcSEcCtD
Fesoterodine—Skin disorder—Gemcitabine—lung cancer	0.000241	0.00134	CcSEcCtD
Fesoterodine—Vision blurred—Paclitaxel—lung cancer	0.00024	0.00133	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.00024	0.00133	CcSEcCtD
Fesoterodine—Dizziness—Topotecan—lung cancer	0.000239	0.00132	CcSEcCtD
Fesoterodine—Dizziness—Erlotinib—lung cancer	0.000236	0.00131	CcSEcCtD
Fesoterodine—Vertigo—Etoposide—lung cancer	0.000234	0.00129	CcSEcCtD
Fesoterodine—Headache—Vinblastine—lung cancer	0.000233	0.00129	CcSEcCtD
Fesoterodine—Angioedema—Paclitaxel—lung cancer	0.000233	0.00129	CcSEcCtD
Fesoterodine—Eye disorder—Docetaxel—lung cancer	0.000232	0.00128	CcSEcCtD
Fesoterodine—Insomnia—Irinotecan—lung cancer	0.000231	0.00128	CcSEcCtD
Fesoterodine—Cardiac disorder—Docetaxel—lung cancer	0.00023	0.00128	CcSEcCtD
Fesoterodine—Infection—Cisplatin—lung cancer	0.00023	0.00127	CcSEcCtD
Fesoterodine—Vertigo—Paclitaxel—lung cancer	0.000229	0.00127	CcSEcCtD
Fesoterodine—Rash—Topotecan—lung cancer	0.000228	0.00126	CcSEcCtD
Fesoterodine—Hypersensitivity—Vinorelbine—lung cancer	0.000228	0.00126	CcSEcCtD
Fesoterodine—Dermatitis—Topotecan—lung cancer	0.000228	0.00126	CcSEcCtD
Fesoterodine—Nervous system disorder—Cisplatin—lung cancer	0.000227	0.00126	CcSEcCtD
Fesoterodine—Cough—Etoposide—lung cancer	0.000227	0.00126	CcSEcCtD
Fesoterodine—Somnolence—Irinotecan—lung cancer	0.000227	0.00126	CcSEcCtD
Fesoterodine—Headache—Topotecan—lung cancer	0.000226	0.00125	CcSEcCtD
Fesoterodine—Tachycardia—Cisplatin—lung cancer	0.000226	0.00125	CcSEcCtD
Fesoterodine—Rash—Erlotinib—lung cancer	0.000225	0.00125	CcSEcCtD
Fesoterodine—Dermatitis—Erlotinib—lung cancer	0.000225	0.00125	CcSEcCtD
Fesoterodine—Palpitations—Paclitaxel—lung cancer	0.000225	0.00125	CcSEcCtD
Fesoterodine—Skin disorder—Cisplatin—lung cancer	0.000225	0.00125	CcSEcCtD
Fesoterodine—Insomnia—Gemcitabine—lung cancer	0.000225	0.00124	CcSEcCtD
Fesoterodine—Dyspepsia—Irinotecan—lung cancer	0.000224	0.00124	CcSEcCtD
Fesoterodine—Headache—Erlotinib—lung cancer	0.000224	0.00124	CcSEcCtD
Fesoterodine—Mediastinal disorder—Docetaxel—lung cancer	0.000224	0.00124	CcSEcCtD
Fesoterodine—Cough—Paclitaxel—lung cancer	0.000222	0.00123	CcSEcCtD
Fesoterodine—Asthenia—Vinorelbine—lung cancer	0.000222	0.00123	CcSEcCtD
Fesoterodine—Chest pain—Etoposide—lung cancer	0.000221	0.00123	CcSEcCtD
Fesoterodine—Nausea—Vinblastine—lung cancer	0.000221	0.00122	CcSEcCtD
Fesoterodine—Somnolence—Gemcitabine—lung cancer	0.000221	0.00122	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Irinotecan—lung cancer	0.00022	0.00122	CcSEcCtD
Fesoterodine—Fatigue—Irinotecan—lung cancer	0.00022	0.00122	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00022	0.00122	CcSEcCtD
Fesoterodine—Pruritus—Vinorelbine—lung cancer	0.000219	0.00121	CcSEcCtD
Fesoterodine—Constipation—Irinotecan—lung cancer	0.000218	0.00121	CcSEcCtD
Fesoterodine—Mental disorder—Docetaxel—lung cancer	0.000217	0.0012	CcSEcCtD
Fesoterodine—Chest pain—Paclitaxel—lung cancer	0.000217	0.0012	CcSEcCtD
Fesoterodine—Face oedema—Doxorubicin—lung cancer	0.000216	0.0012	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000215	0.00119	CcSEcCtD
Fesoterodine—Nausea—Topotecan—lung cancer	0.000215	0.00119	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000214	0.00119	CcSEcCtD
Fesoterodine—Abdominal discomfort—Methotrexate—lung cancer	0.000214	0.00119	CcSEcCtD
Fesoterodine—Fatigue—Gemcitabine—lung cancer	0.000214	0.00119	CcSEcCtD
Fesoterodine—Confusional state—Etoposide—lung cancer	0.000214	0.00119	CcSEcCtD
Fesoterodine—Constipation—Gemcitabine—lung cancer	0.000212	0.00118	CcSEcCtD
Fesoterodine—Nausea—Erlotinib—lung cancer	0.000212	0.00118	CcSEcCtD
Fesoterodine—Dry mouth—Paclitaxel—lung cancer	0.000212	0.00118	CcSEcCtD
Fesoterodine—Diarrhoea—Vinorelbine—lung cancer	0.000212	0.00117	CcSEcCtD
Fesoterodine—Dysgeusia—Docetaxel—lung cancer	0.000212	0.00117	CcSEcCtD
Fesoterodine—Infection—Etoposide—lung cancer	0.000211	0.00117	CcSEcCtD
Fesoterodine—Feeling abnormal—Irinotecan—lung cancer	0.00021	0.00116	CcSEcCtD
Fesoterodine—Confusional state—Paclitaxel—lung cancer	0.00021	0.00116	CcSEcCtD
Fesoterodine—Back pain—Docetaxel—lung cancer	0.000209	0.00116	CcSEcCtD
Fesoterodine—Dysuria—Methotrexate—lung cancer	0.000209	0.00116	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Irinotecan—lung cancer	0.000209	0.00116	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Methotrexate—lung cancer	0.000208	0.00115	CcSEcCtD
Fesoterodine—Tachycardia—Etoposide—lung cancer	0.000207	0.00115	CcSEcCtD
Fesoterodine—Infection—Paclitaxel—lung cancer	0.000207	0.00114	CcSEcCtD
Fesoterodine—Skin disorder—Etoposide—lung cancer	0.000206	0.00114	CcSEcCtD
Fesoterodine—Dry skin—Doxorubicin—lung cancer	0.000205	0.00114	CcSEcCtD
Fesoterodine—Feeling abnormal—Gemcitabine—lung cancer	0.000205	0.00113	CcSEcCtD
Fesoterodine—Dizziness—Vinorelbine—lung cancer	0.000204	0.00113	CcSEcCtD
Fesoterodine—Abdominal pain upper—Doxorubicin—lung cancer	0.000204	0.00113	CcSEcCtD
Fesoterodine—Nervous system disorder—Paclitaxel—lung cancer	0.000204	0.00113	CcSEcCtD
Fesoterodine—Tachycardia—Paclitaxel—lung cancer	0.000203	0.00112	CcSEcCtD
Fesoterodine—Skin disorder—Paclitaxel—lung cancer	0.000202	0.00112	CcSEcCtD
Fesoterodine—Abdominal pain—Irinotecan—lung cancer	0.000202	0.00112	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Cisplatin—lung cancer	0.0002	0.00111	CcSEcCtD
Fesoterodine—Infestation NOS—Methotrexate—lung cancer	0.000199	0.0011	CcSEcCtD
Fesoterodine—Infestation—Methotrexate—lung cancer	0.000199	0.0011	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000197	0.00109	CcSEcCtD
Fesoterodine—Rash—Vinorelbine—lung cancer	0.000195	0.00108	CcSEcCtD
Fesoterodine—Dermatitis—Vinorelbine—lung cancer	0.000195	0.00108	CcSEcCtD
Fesoterodine—Headache—Vinorelbine—lung cancer	0.000194	0.00107	CcSEcCtD
Fesoterodine—Palpitations—Docetaxel—lung cancer	0.000191	0.00106	CcSEcCtD
Fesoterodine—Feeling abnormal—Cisplatin—lung cancer	0.000191	0.00106	CcSEcCtD
Fesoterodine—Somnolence—Etoposide—lung cancer	0.000189	0.00104	CcSEcCtD
Fesoterodine—Cough—Docetaxel—lung cancer	0.000188	0.00104	CcSEcCtD
Fesoterodine—Angina pectoris—Doxorubicin—lung cancer	0.000188	0.00104	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Methotrexate—lung cancer	0.000188	0.00104	CcSEcCtD
Fesoterodine—Insomnia—Paclitaxel—lung cancer	0.000188	0.00104	CcSEcCtD
Fesoterodine—Hypersensitivity—Irinotecan—lung cancer	0.000188	0.00104	CcSEcCtD
Fesoterodine—Somnolence—Paclitaxel—lung cancer	0.000185	0.00102	CcSEcCtD
Fesoterodine—Chest pain—Docetaxel—lung cancer	0.000184	0.00102	CcSEcCtD
Fesoterodine—Nausea—Vinorelbine—lung cancer	0.000184	0.00102	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Etoposide—lung cancer	0.000183	0.00101	CcSEcCtD
Fesoterodine—Dyspepsia—Paclitaxel—lung cancer	0.000183	0.00101	CcSEcCtD
Fesoterodine—Asthenia—Irinotecan—lung cancer	0.000183	0.00101	CcSEcCtD
Fesoterodine—Fatigue—Etoposide—lung cancer	0.000183	0.00101	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000183	0.00101	CcSEcCtD
Fesoterodine—Constipation—Etoposide—lung cancer	0.000181	0.00101	CcSEcCtD
Fesoterodine—Dysuria—Doxorubicin—lung cancer	0.000181	0.001	CcSEcCtD
Fesoterodine—Dry mouth—Docetaxel—lung cancer	0.00018	0.000996	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Doxorubicin—lung cancer	0.00018	0.000996	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00018	0.000995	CcSEcCtD
Fesoterodine—Fatigue—Paclitaxel—lung cancer	0.000179	0.000993	CcSEcCtD
Fesoterodine—Asthenia—Gemcitabine—lung cancer	0.000178	0.000987	CcSEcCtD
Fesoterodine—Constipation—Paclitaxel—lung cancer	0.000178	0.000985	CcSEcCtD
Fesoterodine—Confusional state—Docetaxel—lung cancer	0.000178	0.000985	CcSEcCtD
Fesoterodine—Urinary tract disorder—Methotrexate—lung cancer	0.000177	0.000979	CcSEcCtD
Fesoterodine—Pruritus—Gemcitabine—lung cancer	0.000176	0.000974	CcSEcCtD
Fesoterodine—Urethral disorder—Methotrexate—lung cancer	0.000175	0.000971	CcSEcCtD
Fesoterodine—Infection—Docetaxel—lung cancer	0.000175	0.00097	CcSEcCtD
Fesoterodine—Feeling abnormal—Etoposide—lung cancer	0.000175	0.000968	CcSEcCtD
Fesoterodine—Diarrhoea—Irinotecan—lung cancer	0.000174	0.000967	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Etoposide—lung cancer	0.000173	0.000961	CcSEcCtD
Fesoterodine—Nervous system disorder—Docetaxel—lung cancer	0.000173	0.000958	CcSEcCtD
Fesoterodine—Infestation—Doxorubicin—lung cancer	0.000172	0.000956	CcSEcCtD
Fesoterodine—Infestation NOS—Doxorubicin—lung cancer	0.000172	0.000956	CcSEcCtD
Fesoterodine—Tachycardia—Docetaxel—lung cancer	0.000172	0.000953	CcSEcCtD
Fesoterodine—Feeling abnormal—Paclitaxel—lung cancer	0.000171	0.00095	CcSEcCtD
Fesoterodine—Skin disorder—Docetaxel—lung cancer	0.000171	0.000949	CcSEcCtD
Fesoterodine—Hypersensitivity—Cisplatin—lung cancer	0.000171	0.000945	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Paclitaxel—lung cancer	0.00017	0.000942	CcSEcCtD
Fesoterodine—Diarrhoea—Gemcitabine—lung cancer	0.00017	0.000942	CcSEcCtD
Fesoterodine—Dizziness—Irinotecan—lung cancer	0.000169	0.000934	CcSEcCtD
Fesoterodine—Urticaria—Etoposide—lung cancer	0.000169	0.000934	CcSEcCtD
Fesoterodine—Abdominal pain—Etoposide—lung cancer	0.000168	0.000929	CcSEcCtD
Fesoterodine—Urinary tract infection—Doxorubicin—lung cancer	0.000168	0.000929	CcSEcCtD
Fesoterodine—Eye disorder—Methotrexate—lung cancer	0.000167	0.000926	CcSEcCtD
Fesoterodine—Asthenia—Cisplatin—lung cancer	0.000166	0.00092	CcSEcCtD
Fesoterodine—Cardiac disorder—Methotrexate—lung cancer	0.000166	0.00092	CcSEcCtD
Fesoterodine—Urticaria—Paclitaxel—lung cancer	0.000165	0.000915	CcSEcCtD
Fesoterodine—Abdominal pain—Paclitaxel—lung cancer	0.000164	0.000911	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Doxorubicin—lung cancer	0.000163	0.000904	CcSEcCtD
Fesoterodine—Mediastinal disorder—Methotrexate—lung cancer	0.000161	0.000893	CcSEcCtD
Fesoterodine—Rash—Irinotecan—lung cancer	0.000161	0.000891	CcSEcCtD
Fesoterodine—Dermatitis—Irinotecan—lung cancer	0.000161	0.00089	CcSEcCtD
Fesoterodine—Headache—Irinotecan—lung cancer	0.00016	0.000885	CcSEcCtD
Fesoterodine—Insomnia—Docetaxel—lung cancer	0.000159	0.000883	CcSEcCtD
Fesoterodine—Diarrhoea—Cisplatin—lung cancer	0.000158	0.000878	CcSEcCtD
Fesoterodine—Somnolence—Docetaxel—lung cancer	0.000157	0.000868	CcSEcCtD
Fesoterodine—Mental disorder—Methotrexate—lung cancer	0.000157	0.000868	CcSEcCtD
Fesoterodine—Rash—Gemcitabine—lung cancer	0.000157	0.000868	CcSEcCtD
Fesoterodine—Dermatitis—Gemcitabine—lung cancer	0.000156	0.000867	CcSEcCtD
Fesoterodine—Hypersensitivity—Etoposide—lung cancer	0.000156	0.000866	CcSEcCtD
Fesoterodine—Headache—Gemcitabine—lung cancer	0.000156	0.000862	CcSEcCtD
Fesoterodine—Dyspepsia—Docetaxel—lung cancer	0.000155	0.00086	CcSEcCtD
Fesoterodine—Hypersensitivity—Paclitaxel—lung cancer	0.000153	0.000849	CcSEcCtD
Fesoterodine—Urinary tract disorder—Doxorubicin—lung cancer	0.000153	0.000847	CcSEcCtD
Fesoterodine—Oedema peripheral—Doxorubicin—lung cancer	0.000153	0.000845	CcSEcCtD
Fesoterodine—Dysgeusia—Methotrexate—lung cancer	0.000152	0.000845	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000152	0.000843	CcSEcCtD
Fesoterodine—Asthenia—Etoposide—lung cancer	0.000152	0.000843	CcSEcCtD
Fesoterodine—Fatigue—Docetaxel—lung cancer	0.000152	0.000842	CcSEcCtD
Fesoterodine—Urethral disorder—Doxorubicin—lung cancer	0.000152	0.000841	CcSEcCtD
Fesoterodine—Nausea—Irinotecan—lung cancer	0.000151	0.000839	CcSEcCtD
Fesoterodine—Constipation—Docetaxel—lung cancer	0.000151	0.000835	CcSEcCtD
Fesoterodine—Back pain—Methotrexate—lung cancer	0.000151	0.000834	CcSEcCtD
Fesoterodine—Pruritus—Etoposide—lung cancer	0.00015	0.000831	CcSEcCtD
Fesoterodine—Asthenia—Paclitaxel—lung cancer	0.000149	0.000827	CcSEcCtD
Fesoterodine—Nausea—Gemcitabine—lung cancer	0.000148	0.000818	CcSEcCtD
Fesoterodine—Pruritus—Paclitaxel—lung cancer	0.000147	0.000815	CcSEcCtD
Fesoterodine—Vision blurred—Methotrexate—lung cancer	0.000147	0.000813	CcSEcCtD
Fesoterodine—Rash—Cisplatin—lung cancer	0.000146	0.000809	CcSEcCtD
Fesoterodine—Dermatitis—Cisplatin—lung cancer	0.000146	0.000808	CcSEcCtD
Fesoterodine—Feeling abnormal—Docetaxel—lung cancer	0.000145	0.000805	CcSEcCtD
Fesoterodine—Diarrhoea—Etoposide—lung cancer	0.000145	0.000804	CcSEcCtD
Fesoterodine—Eye disorder—Doxorubicin—lung cancer	0.000145	0.000802	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Docetaxel—lung cancer	0.000144	0.000799	CcSEcCtD
Fesoterodine—Cardiac disorder—Doxorubicin—lung cancer	0.000144	0.000796	CcSEcCtD
Fesoterodine—Diarrhoea—Paclitaxel—lung cancer	0.000142	0.000788	CcSEcCtD
Fesoterodine—Dizziness—Etoposide—lung cancer	0.00014	0.000777	CcSEcCtD
Fesoterodine—Vertigo—Methotrexate—lung cancer	0.00014	0.000775	CcSEcCtD
Fesoterodine—Mediastinal disorder—Doxorubicin—lung cancer	0.00014	0.000773	CcSEcCtD
Fesoterodine—Abdominal pain—Docetaxel—lung cancer	0.000139	0.000772	CcSEcCtD
Fesoterodine—Dizziness—Paclitaxel—lung cancer	0.000138	0.000762	CcSEcCtD
Fesoterodine—Nausea—Cisplatin—lung cancer	0.000138	0.000762	CcSEcCtD
Fesoterodine—Cough—Methotrexate—lung cancer	0.000136	0.000753	CcSEcCtD
Fesoterodine—Mental disorder—Doxorubicin—lung cancer	0.000136	0.000752	CcSEcCtD
Fesoterodine—Rash—Etoposide—lung cancer	0.000134	0.000741	CcSEcCtD
Fesoterodine—Dermatitis—Etoposide—lung cancer	0.000134	0.00074	CcSEcCtD
Fesoterodine—Headache—Etoposide—lung cancer	0.000133	0.000736	CcSEcCtD
Fesoterodine—Flatulence—Doxorubicin—lung cancer	0.000133	0.000736	CcSEcCtD
Fesoterodine—Chest pain—Methotrexate—lung cancer	0.000133	0.000734	CcSEcCtD
Fesoterodine—Dysgeusia—Doxorubicin—lung cancer	0.000132	0.000731	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000132	0.000729	CcSEcCtD
Fesoterodine—Rash—Paclitaxel—lung cancer	0.000131	0.000727	CcSEcCtD
Fesoterodine—Dermatitis—Paclitaxel—lung cancer	0.000131	0.000726	CcSEcCtD
Fesoterodine—Back pain—Doxorubicin—lung cancer	0.00013	0.000722	CcSEcCtD
Fesoterodine—Headache—Paclitaxel—lung cancer	0.00013	0.000722	CcSEcCtD
Fesoterodine—Hypersensitivity—Docetaxel—lung cancer	0.00013	0.00072	CcSEcCtD
Fesoterodine—Confusional state—Methotrexate—lung cancer	0.000128	0.00071	CcSEcCtD
Fesoterodine—Vision blurred—Doxorubicin—lung cancer	0.000127	0.000704	CcSEcCtD
Fesoterodine—Asthenia—Docetaxel—lung cancer	0.000126	0.000701	CcSEcCtD
Fesoterodine—Infection—Methotrexate—lung cancer	0.000126	0.000699	CcSEcCtD
Fesoterodine—Nausea—Etoposide—lung cancer	0.000126	0.000698	CcSEcCtD
Fesoterodine—Pruritus—Docetaxel—lung cancer	0.000125	0.000691	CcSEcCtD
Fesoterodine—Nervous system disorder—Methotrexate—lung cancer	0.000125	0.00069	CcSEcCtD
Fesoterodine—Nausea—Paclitaxel—lung cancer	0.000124	0.000684	CcSEcCtD
Fesoterodine—Skin disorder—Methotrexate—lung cancer	0.000123	0.000684	CcSEcCtD
Fesoterodine—Vertigo—Doxorubicin—lung cancer	0.000121	0.000671	CcSEcCtD
Fesoterodine—Diarrhoea—Docetaxel—lung cancer	0.000121	0.000668	CcSEcCtD
Fesoterodine—Palpitations—Doxorubicin—lung cancer	0.000119	0.00066	CcSEcCtD
Fesoterodine—Cough—Doxorubicin—lung cancer	0.000118	0.000652	CcSEcCtD
Fesoterodine—Dizziness—Docetaxel—lung cancer	0.000117	0.000646	CcSEcCtD
Fesoterodine—Insomnia—Methotrexate—lung cancer	0.000115	0.000637	CcSEcCtD
Fesoterodine—Chest pain—Doxorubicin—lung cancer	0.000115	0.000636	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000114	0.000631	CcSEcCtD
Fesoterodine—Somnolence—Methotrexate—lung cancer	0.000113	0.000626	CcSEcCtD
Fesoterodine—Dry mouth—Doxorubicin—lung cancer	0.000112	0.000622	CcSEcCtD
Fesoterodine—Dyspepsia—Methotrexate—lung cancer	0.000112	0.00062	CcSEcCtD
Fesoterodine—Rash—Docetaxel—lung cancer	0.000111	0.000616	CcSEcCtD
Fesoterodine—Dermatitis—Docetaxel—lung cancer	0.000111	0.000615	CcSEcCtD
Fesoterodine—Confusional state—Doxorubicin—lung cancer	0.000111	0.000615	CcSEcCtD
Fesoterodine—Headache—Docetaxel—lung cancer	0.00011	0.000612	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Methotrexate—lung cancer	0.00011	0.000608	CcSEcCtD
Fesoterodine—Fatigue—Methotrexate—lung cancer	0.00011	0.000607	CcSEcCtD
Fesoterodine—Infection—Doxorubicin—lung cancer	0.000109	0.000606	CcSEcCtD
Fesoterodine—Nervous system disorder—Doxorubicin—lung cancer	0.000108	0.000598	CcSEcCtD
Fesoterodine—Tachycardia—Doxorubicin—lung cancer	0.000107	0.000595	CcSEcCtD
Fesoterodine—Skin disorder—Doxorubicin—lung cancer	0.000107	0.000592	CcSEcCtD
Fesoterodine—Nausea—Docetaxel—lung cancer	0.000105	0.00058	CcSEcCtD
Fesoterodine—Feeling abnormal—Methotrexate—lung cancer	0.000105	0.00058	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Methotrexate—lung cancer	0.000104	0.000576	CcSEcCtD
Fesoterodine—Urticaria—Methotrexate—lung cancer	0.000101	0.000559	CcSEcCtD
Fesoterodine—Abdominal pain—Methotrexate—lung cancer	0.0001	0.000556	CcSEcCtD
Fesoterodine—Insomnia—Doxorubicin—lung cancer	9.95e-05	0.000551	CcSEcCtD
Fesoterodine—Somnolence—Doxorubicin—lung cancer	9.78e-05	0.000542	CcSEcCtD
Fesoterodine—Dyspepsia—Doxorubicin—lung cancer	9.68e-05	0.000537	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Doxorubicin—lung cancer	9.5e-05	0.000526	CcSEcCtD
Fesoterodine—Fatigue—Doxorubicin—lung cancer	9.49e-05	0.000526	CcSEcCtD
Fesoterodine—Constipation—Doxorubicin—lung cancer	9.41e-05	0.000521	CcSEcCtD
Fesoterodine—Hypersensitivity—Methotrexate—lung cancer	9.36e-05	0.000519	CcSEcCtD
Fesoterodine—Asthenia—Methotrexate—lung cancer	9.12e-05	0.000505	CcSEcCtD
Fesoterodine—Feeling abnormal—Doxorubicin—lung cancer	9.07e-05	0.000502	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Doxorubicin—lung cancer	9e-05	0.000498	CcSEcCtD
Fesoterodine—Pruritus—Methotrexate—lung cancer	8.99e-05	0.000498	CcSEcCtD
Fesoterodine—Urticaria—Doxorubicin—lung cancer	8.74e-05	0.000484	CcSEcCtD
Fesoterodine—Abdominal pain—Doxorubicin—lung cancer	8.7e-05	0.000482	CcSEcCtD
Fesoterodine—Diarrhoea—Methotrexate—lung cancer	8.69e-05	0.000482	CcSEcCtD
Fesoterodine—Dizziness—Methotrexate—lung cancer	8.4e-05	0.000466	CcSEcCtD
Fesoterodine—Hypersensitivity—Doxorubicin—lung cancer	8.11e-05	0.000449	CcSEcCtD
Fesoterodine—Rash—Methotrexate—lung cancer	8.01e-05	0.000444	CcSEcCtD
Fesoterodine—Dermatitis—Methotrexate—lung cancer	8e-05	0.000443	CcSEcCtD
Fesoterodine—Headache—Methotrexate—lung cancer	7.96e-05	0.000441	CcSEcCtD
Fesoterodine—Asthenia—Doxorubicin—lung cancer	7.89e-05	0.000437	CcSEcCtD
Fesoterodine—Pruritus—Doxorubicin—lung cancer	7.78e-05	0.000431	CcSEcCtD
Fesoterodine—Nausea—Methotrexate—lung cancer	7.55e-05	0.000418	CcSEcCtD
Fesoterodine—Diarrhoea—Doxorubicin—lung cancer	7.53e-05	0.000417	CcSEcCtD
Fesoterodine—Dizziness—Doxorubicin—lung cancer	7.28e-05	0.000403	CcSEcCtD
Fesoterodine—Rash—Doxorubicin—lung cancer	6.94e-05	0.000384	CcSEcCtD
Fesoterodine—Dermatitis—Doxorubicin—lung cancer	6.93e-05	0.000384	CcSEcCtD
Fesoterodine—Headache—Doxorubicin—lung cancer	6.89e-05	0.000382	CcSEcCtD
Fesoterodine—Nausea—Doxorubicin—lung cancer	6.53e-05	0.000362	CcSEcCtD
Fesoterodine—CYP3A4—Metabolism—ENO2—lung cancer	7.61e-06	0.0001	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HPGDS—lung cancer	7.61e-06	0.0001	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—JUN—lung cancer	7.6e-06	0.0001	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—AKT1—lung cancer	7.57e-06	9.97e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPP2R1B—lung cancer	7.56e-06	9.96e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CASP3—lung cancer	7.5e-06	9.88e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CG—lung cancer	7.49e-06	9.87e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—APC—lung cancer	7.49e-06	9.87e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KIT—lung cancer	7.49e-06	9.87e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—NRAS—lung cancer	7.49e-06	9.87e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL2—lung cancer	7.48e-06	9.86e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—APC—lung cancer	7.46e-06	9.84e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KIT—lung cancer	7.46e-06	9.84e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CG—lung cancer	7.46e-06	9.84e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—NRAS—lung cancer	7.46e-06	9.84e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL6—lung cancer	7.45e-06	9.81e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ABCB1—lung cancer	7.4e-06	9.76e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGF—lung cancer	7.4e-06	9.76e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MMP9—lung cancer	7.4e-06	9.75e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CG—lung cancer	7.39e-06	9.74e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—APC—lung cancer	7.39e-06	9.74e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KIT—lung cancer	7.39e-06	9.74e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—NRAS—lung cancer	7.39e-06	9.74e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTT1—lung cancer	7.38e-06	9.72e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGF—lung cancer	7.38e-06	9.72e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1A—lung cancer	7.37e-06	9.71e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PTEN—lung cancer	7.35e-06	9.69e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGF—lung cancer	7.31e-06	9.63e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCND1—lung cancer	7.3e-06	9.62e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP2A6—lung cancer	7.29e-06	9.61e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GCLC—lung cancer	7.29e-06	9.61e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—JUN—lung cancer	7.28e-06	9.6e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—TYMS—lung cancer	7.27e-06	9.58e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CYP1A1—lung cancer	7.23e-06	9.53e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTM1—lung cancer	7.19e-06	9.47e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—AKT1—lung cancer	7.17e-06	9.46e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ERCC2—lung cancer	7.17e-06	9.45e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—MAPK3—lung cancer	7.17e-06	9.45e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—MAPK3—lung cancer	7.15e-06	9.42e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—POMC—lung cancer	7.13e-06	9.39e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—POMC—lung cancer	7.11e-06	9.36e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—lung cancer	7.08e-06	9.34e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—MAPK3—lung cancer	7.08e-06	9.33e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1A—lung cancer	7.06e-06	9.3e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PTEN—lung cancer	7.04e-06	9.28e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—BRAF—lung cancer	7.04e-06	9.28e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—POMC—lung cancer	7.04e-06	9.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—BRAF—lung cancer	7.02e-06	9.25e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EP300—lung cancer	7.01e-06	9.24e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6R—lung cancer	6.95e-06	9.16e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—BRAF—lung cancer	6.95e-06	9.16e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CREBBP—lung cancer	6.94e-06	9.15e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6R—lung cancer	6.93e-06	9.14e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CREBBP—lung cancer	6.92e-06	9.12e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ENO1—lung cancer	6.91e-06	9.11e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—AKT1—lung cancer	6.87e-06	9.05e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6R—lung cancer	6.86e-06	9.05e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CREBBP—lung cancer	6.85e-06	9.03e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CB—lung cancer	6.84e-06	9.02e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—EGFR—lung cancer	6.82e-06	8.99e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SRC—lung cancer	6.82e-06	8.99e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CYP1A1—lung cancer	6.81e-06	8.98e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—EGFR—lung cancer	6.8e-06	8.96e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTGS2—lung cancer	6.78e-06	8.93e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ERCC2—lung cancer	6.76e-06	8.91e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—EGFR—lung cancer	6.73e-06	8.88e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EP300—lung cancer	6.72e-06	8.85e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—VEGFA—lung cancer	6.64e-06	8.75e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAP2K1—lung cancer	6.63e-06	8.73e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAP2K1—lung cancer	6.61e-06	8.71e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CD—lung cancer	6.58e-06	8.68e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—STAT3—lung cancer	6.58e-06	8.67e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CD—lung cancer	6.56e-06	8.65e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—NRAS—lung cancer	6.56e-06	8.65e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAP2K1—lung cancer	6.54e-06	8.62e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SRC—lung cancer	6.53e-06	8.61e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	6.52e-06	8.59e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	6.5e-06	8.57e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CD—lung cancer	6.5e-06	8.56e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—KRAS—lung cancer	6.44e-06	8.49e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	6.44e-06	8.48e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—KRAS—lung cancer	6.42e-06	8.47e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—KRAS—lung cancer	6.36e-06	8.39e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—VEGFA—lung cancer	6.36e-06	8.38e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—STAT3—lung cancer	6.3e-06	8.3e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK3—lung cancer	6.28e-06	8.28e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—NRAS—lung cancer	6.28e-06	8.28e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—APOA1—lung cancer	6.2e-06	8.18e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP2E1—lung cancer	6.2e-06	8.17e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NQO1—lung cancer	6.13e-06	8.08e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MYC—lung cancer	6.11e-06	8.05e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK3—lung cancer	6.02e-06	7.93e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EGFR—lung cancer	5.98e-06	7.88e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	5.92e-06	7.8e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTEN—lung cancer	5.91e-06	7.79e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	5.9e-06	7.78e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MDM2—lung cancer	5.9e-06	7.77e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MDM2—lung cancer	5.88e-06	7.75e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RAF1—lung cancer	5.88e-06	7.75e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RAF1—lung cancer	5.86e-06	7.72e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MYC—lung cancer	5.85e-06	7.71e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—APOA1—lung cancer	5.85e-06	7.71e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	5.84e-06	7.7e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MDM2—lung cancer	5.82e-06	7.67e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ERBB2—lung cancer	5.81e-06	7.66e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RAF1—lung cancer	5.8e-06	7.65e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ERBB2—lung cancer	5.8e-06	7.64e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ERBB2—lung cancer	5.74e-06	7.56e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CB—lung cancer	5.74e-06	7.56e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MTOR—lung cancer	5.74e-06	7.56e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EGFR—lung cancer	5.72e-06	7.54e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MTOR—lung cancer	5.72e-06	7.54e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CB—lung cancer	5.72e-06	7.54e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CG—lung cancer	5.66e-06	7.47e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CB—lung cancer	5.66e-06	7.47e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MTOR—lung cancer	5.66e-06	7.47e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KRAS—lung cancer	5.65e-06	7.44e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—EP300—lung cancer	5.64e-06	7.43e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—STK11—lung cancer	5.53e-06	7.29e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCL8—lung cancer	5.51e-06	7.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCL8—lung cancer	5.5e-06	7.24e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HRAS—lung cancer	5.48e-06	7.22e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HRAS—lung cancer	5.46e-06	7.2e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCL8—lung cancer	5.44e-06	7.17e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HRAS—lung cancer	5.41e-06	7.13e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KRAS—lung cancer	5.41e-06	7.13e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—POMC—lung cancer	5.39e-06	7.11e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CG—lung cancer	5.34e-06	7.04e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—AKT1—lung cancer	5.33e-06	7.02e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—AKT1—lung cancer	5.31e-06	7e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CASP3—lung cancer	5.28e-06	6.96e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—lung cancer	5.27e-06	6.95e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CASP3—lung cancer	5.26e-06	6.93e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—AKT1—lung cancer	5.26e-06	6.93e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—lung cancer	5.25e-06	6.92e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CREBBP—lung cancer	5.25e-06	6.92e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—lung cancer	5.24e-06	6.91e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—lung cancer	5.23e-06	6.89e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CASP3—lung cancer	5.21e-06	6.87e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—lung cancer	5.2e-06	6.86e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PIK3CA—lung cancer	5.19e-06	6.84e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—lung cancer	5.18e-06	6.82e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCND1—lung cancer	5.14e-06	6.77e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JUN—lung cancer	5.13e-06	6.76e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCND1—lung cancer	5.12e-06	6.75e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTP1—lung cancer	5.11e-06	6.74e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JUN—lung cancer	5.11e-06	6.73e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—POMC—lung cancer	5.08e-06	6.7e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCND1—lung cancer	5.07e-06	6.68e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JUN—lung cancer	5.06e-06	6.67e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—lung cancer	5.02e-06	6.61e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—lung cancer	4.99e-06	6.57e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CD—lung cancer	4.98e-06	6.56e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CAT—lung cancer	4.98e-06	6.56e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—lung cancer	4.97e-06	6.55e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1A—lung cancer	4.97e-06	6.55e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CA—lung cancer	4.97e-06	6.55e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTEN—lung cancer	4.96e-06	6.53e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1A—lung cancer	4.95e-06	6.53e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CREBBP—lung cancer	4.95e-06	6.52e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTEN—lung cancer	4.94e-06	6.51e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—lung cancer	4.92e-06	6.49e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ALB—lung cancer	4.92e-06	6.48e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1A—lung cancer	4.91e-06	6.47e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTEN—lung cancer	4.89e-06	6.45e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ABCB1—lung cancer	4.84e-06	6.38e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—AKT1—lung cancer	4.84e-06	6.38e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—AKT1—lung cancer	4.82e-06	6.36e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—lung cancer	4.81e-06	6.33e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HRAS—lung cancer	4.8e-06	6.33e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—AKT1—lung cancer	4.77e-06	6.29e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—TYMS—lung cancer	4.75e-06	6.27e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EP300—lung cancer	4.73e-06	6.23e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EP300—lung cancer	4.71e-06	6.21e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTM1—lung cancer	4.7e-06	6.19e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CD—lung cancer	4.69e-06	6.18e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EP300—lung cancer	4.67e-06	6.15e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ALB—lung cancer	4.63e-06	6.11e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SRC—lung cancer	4.6e-06	6.06e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HRAS—lung cancer	4.6e-06	6.06e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—lung cancer	4.59e-06	6.05e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SRC—lung cancer	4.58e-06	6.04e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SRC—lung cancer	4.54e-06	5.98e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—VEGFA—lung cancer	4.48e-06	5.9e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—VEGFA—lung cancer	4.46e-06	5.88e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP1A1—lung cancer	4.46e-06	5.87e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—STAT3—lung cancer	4.43e-06	5.84e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NRAS—lung cancer	4.42e-06	5.83e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—VEGFA—lung cancer	4.42e-06	5.83e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—STAT3—lung cancer	4.42e-06	5.83e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ERCC2—lung cancer	4.42e-06	5.82e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NRAS—lung cancer	4.41e-06	5.81e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—lung cancer	4.4e-06	5.8e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—STAT3—lung cancer	4.38e-06	5.77e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NRAS—lung cancer	4.37e-06	5.76e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CB—lung cancer	4.34e-06	5.72e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTGS2—lung cancer	4.3e-06	5.67e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—AKT1—lung cancer	4.24e-06	5.59e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK3—lung cancer	4.24e-06	5.58e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK3—lung cancer	4.22e-06	5.57e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK3—lung cancer	4.18e-06	5.51e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CA—lung cancer	4.17e-06	5.5e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MYC—lung cancer	4.12e-06	5.43e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MYC—lung cancer	4.11e-06	5.41e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CB—lung cancer	4.09e-06	5.39e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MYC—lung cancer	4.07e-06	5.36e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—AKT1—lung cancer	4.06e-06	5.35e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTGS2—lung cancer	4.05e-06	5.34e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGFR—lung cancer	4.03e-06	5.31e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGFR—lung cancer	4.02e-06	5.29e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGFR—lung cancer	3.98e-06	5.24e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—APOA1—lung cancer	3.82e-06	5.04e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KRAS—lung cancer	3.81e-06	5.02e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KRAS—lung cancer	3.8e-06	5e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KRAS—lung cancer	3.76e-06	4.95e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTEN—lung cancer	3.75e-06	4.94e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—EP300—lung cancer	3.58e-06	4.71e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTEN—lung cancer	3.53e-06	4.66e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CA—lung cancer	3.5e-06	4.61e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CG—lung cancer	3.49e-06	4.6e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CA—lung cancer	3.49e-06	4.6e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CA—lung cancer	3.45e-06	4.55e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AKT1—lung cancer	3.41e-06	4.49e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—lung cancer	3.38e-06	4.46e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—lung cancer	3.37e-06	4.45e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—EP300—lung cancer	3.37e-06	4.44e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—lung cancer	3.34e-06	4.4e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—POMC—lung cancer	3.32e-06	4.38e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HRAS—lung cancer	3.24e-06	4.27e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CREBBP—lung cancer	3.24e-06	4.26e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HRAS—lung cancer	3.23e-06	4.25e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HRAS—lung cancer	3.19e-06	4.21e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—lung cancer	3.1e-06	4.08e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—lung cancer	3.09e-06	4.07e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CD—lung cancer	3.07e-06	4.04e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—lung cancer	3.06e-06	4.03e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALB—lung cancer	3.03e-06	3.99e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT1—lung cancer	2.86e-06	3.77e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT1—lung cancer	2.85e-06	3.75e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT1—lung cancer	2.82e-06	3.72e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CB—lung cancer	2.67e-06	3.52e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS2—lung cancer	2.65e-06	3.49e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CA—lung cancer	2.65e-06	3.49e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CA—lung cancer	2.49e-06	3.29e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTEN—lung cancer	2.31e-06	3.05e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—EP300—lung cancer	2.2e-06	2.9e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AKT1—lung cancer	2.16e-06	2.85e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AKT1—lung cancer	2.04e-06	2.68e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.63e-06	2.15e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKT1—lung cancer	1.33e-06	1.76e-05	CbGpPWpGaD
